Abzyme’s strategy and competitive advantage is to use its unique antibody generation technology to develop a suite of modular antibodies with desired attributes that can be used in a simple “plug-and-play” mode to create virtually limitless bispecific products depending on the therapeutic need. Using our domain antibody generation platform, we are able to rapidly expand our proprietary pipeline by generating novel therapeutic antibodies with desired attributes against emerging targets.

The Company employs a hybrid business model where it either collaborates with pharmaceutical partners for antibody development and commercialization including out-licensing its candidates or it invests directly in its own drug development programs. For certain programs, we – are currently seeking strategic collaborations to jointly advance antibody candidates through development and commercialization.